Pascal Soriot
Executive Director, Chief Executive Officer
Pascal joined AstraZeneca as an Executive Director and Chief Executive Officer on 1 October 2012.
A French national, Pascal joined AstraZeneca from Roche AG where he served as Chief Operating Officer of the company’s pharmaceuticals division since 2010.
Prior to that Pascal was Chief Executive Officer of Genentech, where he was credited with leading the successful merger between the San Francisco-based biologics business and Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in the US, Asia and Europe.
Luke Miels
Executive Vice President Global Portfolio &
Product Strategy (GPPS)
Luke started his career in 1995 with AZ in Australia where he was successively a Sales Representative and Product Manager for Plendil and Diprivan.
He joined Aventis in late 2000 as Marketing and Strategic Planning Manager in Australia before being appointed Country Manager for New Zealand in 2002 and subsequently Thailand the following year.
He then transferred to the USA to lead the Analytics and Commercial Effectiveness function of Aventis US. Following the Sanofi-Aventis merger he led the integration office in the US and was appointed Vice President of Sales for Metabolism at the conclusion of the merger.
In 2006 he moved to Basel to join Roche as Head of Metabolism for Global Marketing. Three years later he was appointed to the role of Regional VP Asia Pacific for the Pharmaceuticals Division and joined the Leadership Team of the Pharmaceuticals Division, initially based in Shanghai and more recently in Singapore.
Luke is married with three children and has an MBA from the Macquarie University, Sydney and a BSc Biology from Flinders University in Adelaide.
Mark Mallon
Executive Vice President, International
Mark Mallon is responsible for the growth and performance of AstraZeneca’s International region, which predominantly includes AstraZeneca’s commercial businesses in Asia Pacific, Russia, Latin America, the Middle East and Africa.
Most recently, Mark served as Regional Vice President for Asia Pacific where he was accountable for the growth and performance of the AstraZeneca business in 14 markets. While in this role Mark has also served as President of AstraZeneca China, responsible for the company’s overall operations in China and Hong Kong.
Previously, Mark led the marketing, sales and commercial operations for AstraZeneca K. K. (Japan). Since joining AstraZeneca in 1994, Mark has held a number of additional leadership roles, Including Marketing Company President of the AstraZeneca Italian subsidiary company and Vice President of Marketing and Sales Operations of AstraZeneca’s US business. While in the US, Mark also was a Board Member for the Christiana Care Network, one of the the largest healthcare networks on the East Coast.
Mark received a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business. He is based in Shanghai.
Dr Zhengbin (Bing) Yao
Head of MedImmune Respiratory,
Inflammation & Autoimmune (RIA) iMed
Dr. Zhengbin (Bing) Yao joined MedImmune in 2010 as Senior Vice President and head of the Respiratory, Inflammation, and Immunology (RIA) Innovative Medicines unit. In this role, he leads a cross-functional team dedicated to the development of therapeutic area strategy and advancement of the company’s RIA biologics portfolio. RIA’s focus is to develop biologics as potentially new and exciting treatments for asthma, COPD, idiopathic pulmonary fibrosis, systemic lupus erythematosus, rheumatoid arthritis, and other related diseases.
Bing has 20 years of experience in the leading biotechnology and pharmaceutical companies. Bing previously led the project team leaders’ group for immunology, central nervous system, virology, and metabolism for Genentech research and early development.
Prior to Genentech, he served as Vice President of Research, Acting Head of Clinical, and Corporate Officer for Tanox, and held roles of increasing responsibilities at Aventis, and Amgen.
Bing received his doctorate in microbiology and immunology from the University of Iowa and did his post-doctoral research at Immunex. Bing has authored more than 50 peer reviewed publications and holds over 20 patents and patent applications.
Elisabeth Björk
M.D PhD
Vice President, Head CVMD GMed
& Mölndal Site Lead
Elisabeth is the VP CVMD GMed – the Head of late phase Cardiovascular and Metabolic development unit within AZ. She is leading the development activities across the AZ late phase cardiovascular (mainly Brilinta, Crestor and Epanova), diabetes (mainly Onglyza, Forxiga, Byetta, Bydureon and combinations) and CKD (roxadustat and tenapenaror in development) portfolio.
Prior to taking on this role in June 2012, Elisabeth was Global Product VP for dapagliflozin (approved as Forxiga in Europe and many other countries, including Australia, and as Farxiga in the US), and led the development of this first-in-class drug in partnership with Bristol Myers Squibb. She has also been involved in the delivery of key late phase CVMD and GI projects like Crestor, Nexium, Onglyza, Brilinta and others. She led the team that delivered several CV outcomes studies for Crestor (CORONA, JUPITER, AURORA).
Elisabeth has a passion for patients and science, with a special focus on CV outcomes trials, as well as for developing people and teams and inspire them to achievements they did not think were possible. Elisabeth herself is on a constant learning curve and enjoys doing things she has never done before. Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, and was Head of the Diabetes and Endocrinology Unit at the University Hospital, Uppsala, where she spent 15 years in clinical practice and diabetes research, before joining AZ in 2002.
Susan Galbraith
Head of Innovative Medicines Oncology iMed
Susan Galbraith trained as a Clinical Oncologist in the United Kingdom. She studied Medicine at Manchester and Cambridge Universities. She was admitted to Membership of the Royal College of Physicians in 1992, and then trained in Clinical Oncology in London. She gained Fellowship of the Royal College of Radiologists in 1997. She then completed a PhD at the University of London involving translational work on a vascular-targeting agent.
Susan joined the Clinical Discovery Oncology group at Bristol-Myers Squibb in 2001. Susan was closely involved in the in-licensing of ipilimumab from Medarex, elotuzumab from PDL, the acquisitions of Adnexus and Medarex and research collaborations with Exelixis. She held increasing levels of responsibility becoming VP for Oncology and Immunology Early Development, and then latterly taking on responsibility for the Clinical Biomarker team.
Susan joined AZ in September 2010, as Head of the Oncology iMed responsible for Oncology Discovery and Early Development to Proof of Concept
Mohammed M. Dar, M.D.
Vice President, Oncology Clinical Development
Dr. Dar is the Head of Clinical Development at MedImmune for the Oncology TA. In this role, he is accountable for overseeing the development and execution of all studies involving MedImmune’s clinical stage assets for oncology.
Dr. Dar joined MedImmune in January of 2013 in his current role.
Prior to joining MedImmune, Dr. Dar spent nearly 10 years at GlaxoSmithKline in roles of increasing responsibility focused on early clinical development in oncology. During this time, Dr. Dar led the early clinical development of numerous small molecule kinase inhibitors and large molecules. This included 10 First Time in Human studies, multiple Phase 2 Proof-of-Concepts studies and a variety of clinical pharmacology studies. He was also involved in the successful NDA submission and approval of Votrient for renal cell carcinoma.
Dr. Dar received his Bachelors in Chemistry from the University of North Carolina at Chapel Hill and M.D. from Duke University School of Medicine. He completed his residency in Internal Medicine at Duke University and went on to complete a Fellowship in Hematology and Oncology at the National Institutes of Health.
Rachel Humphrey, M.D.
Head of Immuno-oncology GMed, AZ
Rachel Humphrey, MD, currently heads the late stage Immuno-Oncology department at AZ and is the former Executive VP and Chief Medical Officer for Mirati Therapeutics in San Diego. She may be best known for her work at BMS where she led the clinical development of the CTLA-4 antagonist monoclonal antibody Yervoy, the first immunotherapy to demonstrate survival in patients with metastatic melanoma, including 10-year survival in a subset of patients. As well as supervising a range of alliance and in-licensing projects and new drug filings at BMS, she has also worked in a range of senior clinical development and strategy roles at Bayer Pharmaceuticals, supervising the development of Nexavar, among other anti-cancer agents.
Previously, Rachel was a Staff Physician Scientist at the National Cancer Institute where she completed her Clinical Oncology Fellowship. Board Certified in Internal Medicine with a residency at John Hopkins Hospital, she was educated at Harvard and the Case Western Reserve University (CWRU) Medical School in Cleveland. She has authored more than 20 publications, and an extensive number of abstracts.
Outside of work, Rachel has produced, directed and performed in community theatre productions and is the lead singer of The Checkpoints, a blues band made up of leaders in Immuno-Oncology which routinely plays concerts at ASCO and other clinical cancer congresses.
Briggs Morrison
Executive Vice President, Global Medicines Development
& Chief Medical Officer
Dr. Briggs Morrison leads our global late stage development organisation for both small molecules and biologics and is a member of the AstraZeneca Senior Executive Team. He joined AstraZeneca in 2012 from Pfizer, where he was Head, Medical Excellence, overseeing Development, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health businesses.
Briggs has a track record of successfully developing novel medicines in roles at both Pfizer and Merck. He is the author of many original scientific publications in oncology, in other areas of medicine, and in the conduct of clinical trials.
Briggs received a B.S. (Biology) degree from Georgetown University and an M.D. degree from the University of Connecticut, followed by an internship and residency in Internal Medicine at the Massachusetts General Hospital, a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in Genetics at Harvard Medical School.
Mene Pangalos
Executive Vice President, Innovative Medicines
Mene Pangalos, Ph.D. is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit. A member of the company’s Senior Executive team, Mene has overall responsibility for the company’s small molecule discovery research and early development activities.
As one of AstraZeneca’s leading scientists Mene has published more than 120 peer-reviewed articles in scientific journals and has served as an editor of books and journals in neuroscience. Mene completed his undergraduate degree in Biochemistry at Imperial College of Science and Technology and earned a PhD in Neurochemistry from the Institute of Neurology, both at the University of London. He is a Visiting Professor of Neuroscience at King’s College London.
In the UK, Mene sits on the Medical Research Council (MRC), the council for the National Centre for Universities and Business, the Prime Minister’s Research Champion Group for Dementia and is part of the Ministerial Industry Strategy Group. He is also a Fellow of the Society for Biology, an Associate of the Royal College of Science and holds memberships with the American Society of Neuroscience and the British Pharmacology Society.
Throughout his career Mene has been recognised for driving forward scientific innovation. At Wyeth his group was recognised by R&D Directions magazine as having the Best Central Nervous System Pipeline, while in 2008 Mene was awarded an Innovation in Industry award by the New York Academy of Sciences for his outstanding contribution to neuroscience research and drug discovery.
Since joining AstraZeneca in 2010, Mene has been instrumental in transforming the company’s commitment to science. He has led the transformation of R&D productivity through the development and implementation of the “5R” framework (recently published in Nature Reviews Drug Discovery); driven greater collaboration with academic, NGO and peer organisations; pioneered programmes to promote more open innovation and fostered a science driven culture that rewards truth-seeking behaviours.
Mene is also overseeing the creation of AstraZeneca’s new £330 million research centre in Cambridge - a state of the art of facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.
Bahija Jallal
Executive Vice President, MedImmune
Dr. Bahija Jallal is Executive Vice President of AstraZeneca and head of MedImmune, a global biologics research and development organization with locations in Gaithersburg, California and Cambridge, UK. She is a member of the senior executive team at AstraZeneca reporting to the CEO. Dr. Jallal joined MedImmune in March 2006.
Dr. Jallal is passionate about leading and shaping MedImmune’s rich pipeline of drugs targeting cancer, infections, respiratory and inflammatory diseases, cardio-vascular and metabolic diseases and pain to ultimately develop new medicines for patients.
Dr. Jallal is a member of the Board of Directors of the University of Maryland Health Sciences Research Park Corporation, a non-profit organization that manages biomedical research development at the BioPark. She was recently appointed to the Board of Trustees of The Johns Hopkins University.
Dr. Jallal has authored over 70 peer-reviewed publications and has over 15 patents. She is a member of the American Association of Cancer Research, the American Association of Science and the Pharmacogenomics Working Group. She serves as a member of the Board of Directors for the Association of Women in Science and an advisory member of the Healthcare Business Women’s Association. She was named one of FierceBiotech’s “Women in Biotech” and a “Women Who Mean Business” from the Washington Business Journal. In 2013, Dr. Jallal earned the Grace Award from the Cancer Research Institute.
Prior to joining MedImmune, Dr. Jallal worked with Chiron Corporation where she served as vice president, drug assessment and development, and successfully established the company’s translational medicine group. Prior to Chiron Corporation, she worked at Sugen, Inc. where she held positions of increasing responsibility leading to senior director, research.
Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.
Marc Dunoyer
Executive Director, Chief Financial Officer
Marc joined AstraZeneca in June 2013 as Executive Vice-President, Global Portfolio & Product Strategy before being appointed as an Executive Director and Chief Financial Officer in November 2013. In this role he is responsible for Finance, Corporate Strategy and Investor Relations. Marc is also responsible for AstraZeneca's business in Japan.
A French national with a background in finance and accounting, Marc Dunoyer began his career in the pharmaceutical industry at Roussel Uclaf in Paris in the 1970s before becoming President, Japan and then President, Asia Pacific. After returning to France for a period as Managing Director, Global Pharmaceuticals Division, in the 1990s, Marc was appointed President & CEO, Asia Pacific & Japan for Hoechst Marion Roussel in 1995. In 2000, he joined Glaxo Wellcome − just ahead of the merger that created GlaxoSmithKline − as Regional President, Japan and subsequently Regional President, Asia Pacific & Japan. His most recent role before joining AstraZeneca was Global Head of Rare Diseases and (concurrently) Chairman, GSK Japan. Marc has an MBA from the Hautes Études Commerciales and a Bachelor of Law degree from Paris University. He qualified as a Junior Certified Public Accountant in France.
James Ward-Lilley
Vice President Respiratory, Inflammation
& Autoimmunity, GPPS
In April 2013, James Ward-Lilley was appointed Vice President Respiratory, Inflammation and Autoimmunity (RIA) Therapy Area, Global Product and Portfolio Strategy (GPPS). In his role, James leads a cross functional-team driving development and execution of the global therapy area strategy for the company. Through his leadership, his team is successfully delivering growth from the on-market portfolio, readying commercialization of pipeline products and carrying out strategic partnerships that complement AstraZeneca’s pursuit of industry leadership in RIA.
Prior to his current role, James served as Vice President of Investor Relations for the company, successfully leading AZ’s interactions with the company’s investors in a period of significant challenge and change, including the transition of chairman and CEO.
Ward-Lilley has worked in the pharmaceutical industry since 1987, where he began in a sales role for Stuart Pharmaceuticals, a subsidiary of ICI. Progressing through a series of management, marketing and strategy positions with Zeneca Pharmaceuticals, he ultimately served as Director of Integration in UK during the merger of Astra Pharmaceuticals and Zeneca in 1999. From 2001 to 2002 he was the Commercial Director of AstraZeneca’s International Sales & Marketing Organisation after which he was named Marketing Company President of AstraZeneca Belgium & Luxembourg from 2002 to 2005. In 2005, James was appointed Marketing Company President of AstraZeneca China & Hong Kong. In May 2008, James became Regional Vice President for the Central Eastern Europe Middle East & Africa (CEEMEA) region where he was responsible for managing sales and marketing in 70 countries, with sales of >$2bn and more than 4,400 dedicated employees in 53 countries.
James holds a BA (Hons) in Geography from Liverpool University, a Diploma in Marketing and MBA
Fouzia Laghrissi Thode, M.D.
Vice President, Therapy Area,
Cardiovascular & Metabolism
Fouzia Laghrissi-Thode, MD has been appointed as Therapy Area Vice President, Cardiovascular and Metabolic Disease (CVMD), GPPS in September 2013. She worked close to 20 years in the pharmaceutical industry, with demonstrated success in a wide range of areas including clinical development, strategic and global marketing, business development & licensing, and product strategy.
In her most recent role as Head of Global Product Strategy for Cardio Metabolism and Anaemia at Roche, Fouzia has been at the centre of very large programs in cardiovascular and diabetes. She led the Franchise Leadership Team responsible for Bonviva, NeoRecormon, Mircera and the overall cardiometabolism portfolio. Through her previous business development and licensing roles, she has a proven track record for working in collaborations, strategic partnerships and joint ventures. She also served as a chair of the Joint Commercial Committee with GlaxoSmithKline for Bonviva and the Joint Development Committee of the cholesteryl ester transfer protein (CETP) inhibitor program with Japan Tobacco.
Fouzia has worked at Roche, Novartis and Sandoz across a broad range of therapy areas including Central Nervous System (CNS) and Genito-Urinary, with a hallmark of her success being the ability to bridge science with patient needs and commercial objectives. She is serving since 2007 as a Board member of the Healthcare Business Women Association HBA Europe and was recognized by HBA in 2012 for her work in developing and promoting women leadership in healthcare.
Fouzia holds a Doctorate in Medicine (MD) and a Certificate in Pharmaceutical Medicine. She is Board Certified in Psychiatry and has since 1992 a faculty appointment as Adjunct Professor of Psychiatry at the University of Pittsburgh in the US.
Tom Keith Roach
Vice President, Brilinta
Tom joined AstraZeneca in 2003 as Strategy and BD Director of the AsiaPac region based in Singapore. From 2006 to 2008 he was VP Specialty Care for China based in Shanghai and from 2008 to 2010 Marketing Company President for AstraZeneca Korea based in Seoul.
In 2010 Tom moved back to Brussels as AVP Eastern Europe to lead Astrazeneca’s business in Turkey, Central & Eastern Europe, Baltics, Balkans and CIS.
He then moved to his current role in May 2013 to lead the turnaround of the Brilinta Franchise as part of the GPPS leadership team based in Cambridge. Prior to AZ Tom worked in consulting and venture capital from 1994-2001. He served as a Lieutenant in the British Army in the Arctic Circle from 1990-1991 and has a BA and MA in Economics from Jesus College Cambridge. Tom is married to Vicky and has three children, Mack (8), Lyla (7) and Annie (2).
Mondher Mahjoubi M.D.
Senior Vice President, Oncology, GPPS
Mondher Mahjoubi, MD joined AstraZeneca in November 2013, to lead the Oncology therapy area within GPPS and is a member of the GPPS Leadership Team, and is based in Gaithersburg.
Oncology is a core therapy area of focus for us and in addition to our long history with established brands such as Faslodex, Zoladex, Arimidex, Casodex, Iressa and Caprelsa, we have more recently gained momentum in growing our innovative portfolio of immune mediated therapies and those targeting DNA damage and repair. Mondher will be focused on progressing the acceleration of key products including olaparib, AZD9291, MEDI4736 and selumetinib, but also identifying potential biologically synergistic combinations for small and large molecules in order to achieve our vision of building a world class Oncology franchise.
He brings a wealth of experience in the field of oncology to AstraZeneca having held senior positions in the pharmaceutical and biotechnology industry for over 22 years. Most recently he was the SVP global product strategy in Oncology at Genentech, based in San Francisco, where he was responsible for providing strategic business direction from research through to development, commercialization and medical excellence, led the development of disease area strategy for various tumour types / indications and the life-cycle management of the late stage oncology portfolio. Prior to that he was the global head of medical affairs-oncology at Roche, based in Basel where he contributed to build up GMA capabilities and lead the development and implementation of key strategic medical affairs trials in oncology.
Mondher has also held various senior global and affiliate-based positions in marketing and medical affairs for pharmaceutical companies including Mayne Pharma, Sanofi-Aventis, and Rhone Poulenc Rorer based in London, New Jersey and Paris respectively.
He holds a Doctorate in Medicine (MD) and a Certification in Medical Oncology and Clinical Research and Methology, and trained as a medical oncologist and in general surgery and internal medicine. He is also a member of the American Society of Clinical Oncology and European Society of Medical Oncology.
Mondher is married with two daughters, enjoys sports and painting in his spare time and speaks four languages.
Charles (Chuck) Bramlage
President, CEO of Pearl Therapeutics,
Respiratory GMed Head of AstraZeneca
Mr. Bramlage is currently chief executive officer of Pearl Therapeutics. He previously was president of pharmaceutical products at Covidien plc. Earlier, Chuck served as president of European operations at Valeant Pharmaceuticals International and president and chief executive officer of BattellePharma, Inc., a specialty pharmaceutical company developing inhaled products. In addition, he was formerly the vice president of respiratory global commercial development and vice president of U.S. respiratory and cardiovascular marketing for GlaxoSmithKline, where he led the team responsible for the global launch of Seretide®/Advair® and the U.S. launch of Flovent®.
His earlier career involved various positions at GSK and Merck in product management, sales management, sales, and sales training. He and his teams have launched over 40 brands in 14 therapeutic areas.
Mr. Bramlage holds an MBA from the University of Dayton and a BS Administrative Science in Marketing from The Ohio State University.
Maarten Kraan
Head of Innovative Medicines
Respiratory & Inflammation iMed
Dr Maarten Kraan MD PhD, joined AstraZeneca in 2010 where he build the Respiratory & Inflammation iMed based in Mölndal, Sweden.
After an initial career as physiotherapist he completed Medical School in Leiden The Netherlands in 1991, where he also completed his training as an internist/rheumatologist in 1998 and his PhD programme on synovial tissue analysis in 2000. 1998 he moved to the University of Amsterdam as an Associate Professor, focusing on translational medicine. In this period he was lead investigator in numerous clinical trials in rheumatoid and psoriatic arthritis.
In 2003, he joined Schering Plough in Kenilworth, NJ, to build a translational medicine unit in the area of inflammation. He was also heavily involved in the development of both small molecule and large molecule programs in these disease areas. In 2008, Maarten joined Bristol-Myers Squibb in Princeton, NJ, to head the Immunoscience group, supporting the commercialization of products such as abatacept and belatacept. In 2009, he became the global head of the inflammation translational medicine group at Roche in Nutley, NJ, which focuses on COPD, asthma and autoimmune diseases with an opportunistic approach to other inflammatory diseases.
Antoine Yver MD MSc
Head of Oncology
GMed & GMD China Lead
Dr. Antoine Yver leads our Oncology Global Medicines Development organisation for both small molecules and biologics – other than immuno-oncology, as well as the GMD organisation for China. He joined AstraZeneca in 2009 after 19 years in the thick of oncology global drug development, in France, the UK and since 1998 in the USA, working for Schering-Plough/Merck, Johnson & Johnson, Aventis and its predecessor Rhône-Poulenc Rorer.
Antoine has a track record of successfully leading the global clinical development of novel small and large molecules oncology medicines, such as Granocyte®, Sylatron®, Yondelis®, Caprelsa®, as well as successfully delivering major line extensions for Taxotere® and Doxil® and contributing to significant in-licensing business development deals. In recent years, Antoine led the acceleration of the AZ MedI late stage development oncology pipelines, including in particular olaparib, selumetinib, cediranib, Iressa® and AZD9291, as well as facilitating the transition of PDL1 Medi4736 to late stage development prior to the creation of the Immuno-Oncology GMed.
Antoine, a paediatrician oncologist by training and practice, received his MSc and MD degrees from University of Paris, France and held a full time academic appointment as Chef de Clinique Assistant des Hôpitaux in Paris prior to joining industry in 1990.
Peter Emtage,
Vice President
Peter Emtage is the VP of Immune Mediated Therapy in Oncology Innovative Medicines Unit (iMed) at MedImmune, the biologics arm of AstraZeneca. Prior to joining Medimmune, Peter held senior positions at Femta, Nventa, Biomira, and Nuvelo. Peter is an immunologist by training and has focused during the past 15 years on developing drugs to modulate the immune response in humans. He has focused on infectious disease and tumor vaccines using viral and non-viral delivery systems, chimeric antigen receptor and TCR adoptive T cells modalities, adjuvant and monoclonal antibody development. He has advanced drugs from early pre-clinical through IND submission and into late stage clinical development. Peter was an Instructor in Medicine at the Harvard Institutes of Health, Harvard Medical School. He also has held positions at Aventis Pasteur and the National Cancer Institute
